Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nyasol SCHEMBL8416158 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL776219 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL776218 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| Nyasol SCHEMBL30712027 | 1.00 | APP (0.43) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL13558420 | 0.92 | CYP3A4 (0.46) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL7861271 | 0.92 | CYP3A4 (0.46) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL799612 | 0.90 | MAOB (0.39) | APPESR1ESR2MAOBAKR1B1 | |
| SCHEMBL805124 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT | |
| SCHEMBL7861615 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT | |
| SCHEMBL7864584 | 0.87 | MAPT (0.50) | ESR2PTGS2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| WO-2010120029-A1 | COMPOSITION COMPRISING THE EXTRACT OF ANEMARRHENA ASPHODELOIDES BUNGE OR THE COMPOUNDS ISOLATED FROM THE SAME FOR PREVENTING AND TREATING LIPID METABOLISM DISORDER | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | APP 698/4885ESR1 2003/4885ESR2 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.